

Publications arising from the Gynaecological Oncology Biobank at Westmead

1. Sinosich MJ, Dodd J, Hudson CN, Tyler JR, Seppala M, Grudzinskas JG & Saunders DM. *The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells.* Tumour Biology 6: 233-242, 1985.
2. Toppila M, Tyler JP, Fay R, Baird PJ, Crandon AJ, Eastman CJ & Hudson CN. *Steroid receptors in human ovarian malignancy. A review of four years tissue collection.* British Journal of Obstetrics & Gynaecology 93: 986-992, 1986.
3. Friedlander ML, Quinn MA, Fortune D, Foo MS, Toppila M, Hudson CN & Russell P. *The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors.* Gynecologic Oncology 32: 184-190, 1989.
4. Boltz EM, Kefford RF, Leary JA, Houghton CR & Friedlander ML. *Amplification of c-ras-Ki oncogene in human ovarian tumours.* Int J Cancer 43: 428-430, 1989.
5. Boltz EM, Harnett P, Leary J, Houghton R, Kefford RF & Friedlander ML. *Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting.* British Journal of Cancer 62: 23-27, 1990.
6. Chenevix-Trench G, Leary J, Kerr J, Michel J, Kefford R, Hurst T, Parsons PG, Friedlander M & Khoo SK. *Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.* Oncogene 7: 1059-1065, 1992.
7. Leary JA, Edwards BG, Houghton CRS, Kefford RF & Friedlander ML. *Amplification of HER-2/neu oncogene in human ovarian cancer.* Int J Gynecol Cancer 2: 291-294, 1992.
8. Leary JA, Doris CP, Boltz EM, Houghton CRS, Kefford RF & Friedlander ML. *Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer.* Int J Gynecol Cancer 3: 293-298, 1993.
9. Chenevix-Trench G, Kerr J, Friedlander M, Hurst T, Sanderson B, Cogan, M, Ward B, Leary J & Khoo SK. *Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors.* American Journal of Human Genetics. 55: 143-149, 1994.
10. Jones SL, Hickson ID, Harris AL & Harnett PR. *Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma.* Int J Cancer. 59: 388-393, 1994.
11. Leary JA, Kerr J, Chenevix-Trench G, Doris CP, Hurst T, Houghton CR & Friedlander ML. *Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer.* Int J Cancer 64: 189-195, 1995.
12. Chenevix-Trench G, Kerr J, Hurst T, Shih Y-C, Purdie D, Bergman L, Friedlander M, Sanderson B, Zournazi A, Coombs T, Leary JA, Crawford E, Shelling AN, Cooke I, Ganesan TS, Searle J, Choi C, Barrett JC, Khoo S-K & Ward B. *Analysis of loss of heterozygosity and K-RAS2 mutations in ovarian neoplasms: clinicopathological correlations.* Genes, Chromosomes and Cancer 18: 75-83, 1996.
13. Kavallaris M, Leary JA, Barrett JA & Friedlander ML. *MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors.* Cancer Lett. 102: 7-16, 1996.
14. Kerr J, Leary JA, Hurst T, Shih Y-C, Antalis TM, Friedlander M, Crawford E, Khoo SK, Ward B & Chenevix-Trench G. *Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus.* Oncogene 13: 1815-1818, 1996.
15. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA & Reddel R. *Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.* Nature Medicine 3:1271-1274, 1997.

16. Pribill I, Speiser P, Leary J, Leodolter S, Hacker NF, Friedlander ML, Birnbaum D, Zeillinger R & Krainer M. *High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma*. Cancer Genetics & Cytogenetics 129: 23-29, 2001.
17. Byrne J, Balleine R, Schoenberg-Fejzo M, Mercieca J, Chiew Y-E, Livnat Y, St. Heaps L, Peters G, Byth K, Karlan B, Slamon D, Harnett PR, & deFazio A. *Tumor Protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian carcinoma*. Int J Cancer 117: 1049-1054, 2005.
18. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA & Stratton MR. *Patterns of somatic mutation in human cancer genomes*. Nature 446: 153-158, 2007.
19. Catchpole D, deFazio A, Devereux L, Fleming M, Hof M, Schmidt C, Thorne H, Zeps N. *The importance of biorepository networks: The Australasian Biospecimen Network-Oncology*. Australian Journal of Medical Science 28: 16-20, 2007.
20. Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, Australian Ovarian Cancer Study Group, deFazio A, Fox SB, Brenton JD, Bowtell DD & Dobrovic A. *High resolution melting for mutation scanning of TP53 exons 5-8*. BMC Cancer 7:168, 2007.
21. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung J, Chiew Y-E, Haviv I, AOCs Study Group, Gertig D, deFazio A & Bowtell DDL. *Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome*. Clin Cancer Res 14: 5198 - 5208, 2008.
22. Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR & deFazio, A. *Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin-sensitivity expressed in ovarian cancer*. Clin Cancer Res 14: 6924-6932, 2008.
23. Anglesio M, Arnold J, George J, Tinker A, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer M, Australian Ovarian Cancer Study Group, deFazio A, Chenevix-Trench G & Bowtell D. *Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of the RAS-MAPK pathway in ovarian serous LMP tumors*. Mol Cancer Res 6: 1678-1690, 2008.
24. Etemadmoghadam D, deFazio A, Beroukhi R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, AOCs Study Group, Harnett PR, Lade S, Akslen LA, Tinker A, Locandro B, Alsop K, Chiew Y-E, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M & Bowtell D. *Integrated genome-wide DNA Copy Number and expression analysis identifies distinct mechanisms of primary chemo-resistance in ovarian carcinomas*. Clin Cancer Res 15:1417-1427, 2009.
25. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover M, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DDL, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M & Huntsman DG. *Mutation of FOXL2 in granulosa-cell tumours of the ovary*. New Engl J Med 360(26): 2719-29, 2009.

26. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, deFazio A, Bowtell D & Brenton JD. *Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary*. The Journal of Pathology 221: 49-56, 2010.
27. Gorringer KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Australian Ovarian Cancer Study, Smyth GK, Campbell IG & Bowtell DDL. *Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer*. PLoS ONE 5(9): e11408, 2010.
28. Johal H, Faedo M, Faltas J, Lau A, Mousina R, Cozzi P, DeFazio A & Rawlinson W. *DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones*. J Med Virol 82: 1044-50, 2010.
29. Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J, Australian Ovarian Cancer Study Group, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DDL, Harnett PR, deFazio A. *Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis*. PLoS ONE 6(3): e17617, 2011.
30. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard, KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale, AL, Huntsman DG, DeFazio A, Creighton CJ, Smyth GK, and Bowtell DDL. *Deregulation of MYCN, LIN28 and Let7 in a molecular subtype of aggressive high-grade serous ovarian cancers*. PLoS ONE 6(4): e18064, 2011.
31. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart D, Bowtell DDL for the Australian Ovarian Cancer Study Group and Matulonis UA. *Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome*. Clin Cancer Res 18(20): 5806-5815, 2012.
32. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, et al. *High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival*. PLoS ONE 8(1): e54356, 2013.
33. Hedditch E, Gao B, Russell A, Lu Y, Emmanuel C, Beesley J, Johnatty S, Chen X, Harnett P, George J, Australian Ovarian Cancer Study Group, Williams R, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann M, Ekici A, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Tanja P, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kruger Kjaer S, Jensen A, Hogdall C, Lundvall L, Engelholm S, Brown B, Flanagan J, Metcalf M, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber R, Berchuck A, Goode E, Bowtell D, Chenevix-Trench G, DeFazio A, Norris M, MacGregor S, Haber M, and Henderson M. *ABCA transporter gene expression is associated with poor outcome in epithelial ovarian cancer*. J Natl Cancer Inst 106(7):dju149, 2014
34. Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L for the Australian Ovarian Cancer Study (AOCS), Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DDL, and deFazio A. *Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver*. Clin Cancer Res 20(24):1-13, 2014

35. Patch A*, Christie E*, Etemadmoghadam D*, Garsed D*, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey P, Kassahn K, Newell F, Quinn M, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong H, The Australian Ovarian Cancer Study Group, Hamilton A, Mileskin L, Au-Yeung G, Kennedy C, Hung J, Chiew Y-E, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller D, Arnau G, Tothill R, Holloway T, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner T, Christ A, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor D, Xu Q, Fink J, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj S, Markham E, Wilson P, Ellul J, McNally O, Doyle M, Vedururu R, Stewart C, Lengyel E, Pearson J, Waddell N, deFazio A**, Grimmond S**, Bowtell D** (*, ** authors contributed equally) *Whole genome characterisation of chemoresistant ovarian cancer*. Nature. (accepted 1 March 2015).
36. Johnatty S, Tyrer J, Kar S, Beesley J, Lu Y, Gao B, Fasching P, Hein A, Ekici A, Beckmann M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Rossing MA, Doherty J, Chang-Claude J, Modugno F, Ness R, Moysich K, Levine D, Kiemeny L, Massuger L, Gronwald J, Lubinski J, Brinton L, Lissowska J, Wentzensen N, Song H, Rhenius V, Campbell I, Eccles D, Sieh W, Whittemore A, McGuire V, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Gayther S, Gentry-Maharaj A, Menon U, Ramus S, Pearce C, Pike M, Stram D, Wu A, Kupryjanczyk J, Dansonka-Mieszkowska A, Rzepecka I, Spiewankiewicz B, Goodman M, Wilkens L, Carney M, Thompson P, Heitz F, du Bois A, Schwaab I, Harter P, Pisterer J, Hillemanns P, Karlan B, Walsh C, Lester J, Orsulic S, Winham S, Earp M, Larson M, Fogarty Z, Høgdall E, Jensen A, Kruger Kjaer S, Fridley B, Cunningham J, Vierkant R, Schildkraut J, Iversen E, Terry K, Cramer D, Bandera E, Orlow I, Pejovic T, Bean Y, Høgdall C, Lundvall L, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Sellers T, Kennedy C, Chiew YE, Berchuck A, Macgregor S, Pharoah P, Goode E, deFazio A, Webb P, and Chenevix-Trench G. *Genome-wide multivariate analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium*. Clin Cancer Res (accepted 4 May 2015).